Hepion Pharmaceuticals, Inc. (HEPA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Hepion Pharmaceuticals, Inc. (HEPA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hepion Pharmaceuticals, Inc. ever had a stock split?
Hepion Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gary S. Stetz CEO | NASDAQ (CM) Exchange | 426897401 CUSIP |
| US Country | 2 Employees | 3 Jun 2019 Last Dividend | 18 Mar 2025 Last Split | 11 Feb 2014 IPO Date |
Overview
Hepion Pharmaceuticals, Inc. is a biopharmaceutical entity primarily engaged in the innovation of therapeutic solutions aimed at the treatment of chronic liver diseases. The company’s operational focus is largely centered within the United States. Initially known as ContraVir Pharmaceuticals, Inc., it underwent a name change to Hepion Pharmaceuticals, Inc. in July 2019. Since its inception in 2013, the company has made considerable strides in advancing its research and development initiatives from its headquarters situated in Edison, New Jersey. Hepion Pharmaceuticals, Inc. is diligently working towards addressing the complex challenges associated with liver diseases through the development of its hallmark drug therapy, Rencofilstat.
Products and Services
Rencofilstat: This pioneering compound developed by Hepion Pharmaceuticals, Inc. serves as a cyclophilin inhibitor. It has successfully progressed through Phase 2a clinical trials, showcasing its potential as a versatile treatment option targeting various pathological pathways that contribute to the advancement of liver disease. Rencofilstat is currently in Phase 2 clinical development specifically for treating non-alcoholic steatohepatitis (NASH). Its therapeutic efficacy extends to the reduction of liver fibrosis, inflammation, tumor burden, and shows promising antiviral activities for hepatitis B, C, and D viruses (HBV, HCV, HDV) along with HIV-1 through multiple mechanisms. The preclinical studies of Rencofilstat have been critical in demonstrating its potential not only as a treatment for NASH but also for its antiviral capabilities, making it a multifaceted drug candidate.
